Abstract: Objective The aim of this study was to investigate the clinical efficacy of tenofovir amibufenamide (TMF) in combination with diammonium glycyrrhizinate in treatment of patients with chronic hepatitis B (CHB). Methods A total of 112 patients with CHB were enrolled in our hospital, and were randomly assigned to receive oral TMF in 56 cases in the control group or TMF in combination with diammonium glycyrrhizinate in another 56 cases in the observation group for 48 weeks. Serum HBV DNA loads were detected by fluorescence quantitative PCR. Serum and blood parameters were routinely obtained for calculation of fibrosis index based on the 4 factors (FIB-4). Lliver stiffness measurement (LSM) was measured by Fibroscan. Results At presentation, serum HBV DNA loads in the two groups were(7.3±1.2)lg copies/mL and (7.5±1.3)lg copies/mL(P>0.05), by end of 48-week treatment, they were (1.3±0.2)lg copies/mL and (1.3±0.3)lg copies/mL(P>0.05), and serum HBV DNA negative rates in the two groups were both 100.0%(P>0.05); serum ALT and AST in the observation group were (39.6±1.1)U/L and (34.2±14.5)U/L, both significantly lower than [(54.2±5.6)U/L and (43.8±16.3)U/L, respectively, P＜0.05] in the control; the FIB-4 score was (1.8±0.3), much lower than [(2.1±0.4),P＜0.05] in the control, while the LSM[(6.7±1.0)kPa vs. (6.8±1.3)kPa] were not significantly different between the two groups (P>0.05); incidences of adverse effects in the two groups(17.9% vs. 14.3%)was not significantly different (P>0.05). Conclusion The combination of TAF and diammonium glycyrrhizinate in the treatment of patients with CHB is satisfactory, which might improve liver function tests normal.

Key words: Hepatitis B, Tenofovir amibufenamide, Diammonium glycyrrhizinate, Therapy